Oxidation chemistry of catecholamines and neuronal degeneration: An update

Current Medicinal Chemistry

Volumn 18, Issue 12, 2011, Pages 1832-1845

  Napolitano, A ^a   Manini, P ^a   D'Ischia, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biological thiol conjugates; Catecholamines; Isoquinolines; Neuromelanin; O quinones quinonemethides

Indexed keywords

ALDEHYDE DERIVATIVE; CATECHOLAMINE; CYSTEINE; DOPAMINE; GLYOXAL; IRON; NEUROMELANIN; NEUROTRANSMITTER; NORADRENALIN; TETRAHYDROISOQUINOLINE;

ARTICLE; CATECHOLAMINE NERVE CELL; CELL FUNCTION; CORRELATION ANALYSIS; CYCLIZATION; DEPLETION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; LIPID PEROXIDATION; MACROMOLECULE; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PEROXIDATION; PICTET SPENGLER REACTION;

CATECHOLAMINES; DOPAMINE; HUMANS; NERVE DEGENERATION; NOREPINEPHRINE; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 79955679714     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795496863     Document Type: Article

References (166)

1. Jenner, P.; Olanow, C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47, S161-S170. (Pubitemid 26422582)
2. Gotz, M.E.; Kunig, G.; Riederer, P.; Youdim, M.B. Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 1994, 63, 37-122. (Pubitemid 24250150)
3. Andersen, J.K. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 2004, 10, S18-S25. (Pubitemid 38901863)
4. Olanow, C.W.; Jenner, P.; Tatton, N.A.; Tatton, W.G. In Parkinson's disease and movement disorders; Jankovic, J., Tolosa, E., Eds.; Williams & Wilkins: Baltimore, 1998; pp. 67-103.
5. Butterfield, D.A.; Castegna, A.; Lauderback, C.M.; Drake, J. Evidence that amyloid beta-peptide induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 2002, 23, 655-664. (Pubitemid 35217687)
6. Perez-Neri, I.; Ramirez-Bermudez, J.; Montes, S.; Rios, C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006, 31, 1279-1294. (Pubitemid 44701776)
7. Albers, D.S.; Augood, S.J. New insights into progressive supranuclear palsy. Trends Neurosci. 2001, 24, 347-353.
8. Browne, S.E.; Ferrante, R.J.; Beal, M.F. Oxidative stress in Huntington's disease. Brain Pathol. 1999, 9, 147-163. (Pubitemid 29056525)
9. Minghetti, L.; Greco, A.; Cardone, F.; Popolo, M.; Ladogana, A.; Almonti, S.; Cunningham, C.; Perry, V.H.; Pocchiari, M.; Levi, G. Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopaties. J. Neuropathol. Exp. Neurol. 2000, 59, 866-871.
10. Calabrese, V.; Lodi, R.; Tonon, C.; D'Agata, V.; Sapienza, M.; Scapagnini, G.; Mangiameli, A.; Pennisi, G.; Stella, A.M; Butterfield, D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 2005, 233, 145-162. (Pubitemid 40812334)
11. Cookson, M.R.; Shaw, P.J. Oxidative stress and motor neurone disease. Brain Pathol. 1999, 9, 165-186. (Pubitemid 29056526)
12. Chinta, S.J.; Andersen, J.K. Redox imbalance in Parkinson's disease. Biochim. Biophys. Acta 2008, 1780, 1362-1367.
13. Berman, S.B.; Hastings, T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73, 1127-1137. (Pubitemid 29395471)
14. Naoi, M.; Maruyama, W.; Yi, H.; Inaba, K.; Akao, Y.; Shamoto-Nagai, M. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J. Neural Transm. 2009, 116, 1371-1381
15. Naoi, M.; Maruyama, W.; Shamoto-Nagai, M.; Yi, H.; Akao, Y.; Tanaka, M. Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders. Mol. Neurobiol. 2005, 31, 81-93. (Pubitemid 41271195)
16. Pearce, R.K.; Owen, A.; Daniel, S.; Jenner, P.; Marsden, C.D. Alteration in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 1997, 104, 661-667.
17. Hald, A.; Lotharius, J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exper. Neurol. 2005, 193, 279-290. (Pubitemid 40616179)
18. Zecca, L.; Youdim, M.B.; Riederer, P.; Connor, J.R.; Crichton, R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5, 863-873. (Pubitemid 39482155)
19. Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fardello, R.G.; Karatekin, E.; Kleinman, M.H.; Turro, N.; Hornykiewicz, O.; Zucca, F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. USA 2004, 101, 9843-9848. (Pubitemid 38869324)
20. Sanchez-Ramos, J.; Overvik, E.; Ames, B.N. A marker of oxyradicalmediated DNA damage (8-hydroxy-2'-deoxyguanosine) is increased in nigro- striatum of Parkinson's disease brain. Neurodegeneration 1994, 3, 197-204.
21. Alam, Z.I.; Jenner, A.; Daniel, S.E.; Lees, A.J.; Cairns, N.; Marsden, C.D.; Jenner, P.; Halliwell, B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997, 69, 1196-1203. (Pubitemid 27364841)
22. Zhang, J.; Perry, G.; Smith, M.A.; Robertson, D.; Olson, S.J.; Graham, D.G.; Montine, T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999, 154, 1423-1429. (Pubitemid 29226437)
23. Nishioka, N.; Arnold, S. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry 2004, 12, 167-175. (Pubitemid 38250300)
24. Jakel, R.J.; Maragos, W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. TINS 2000, 23, 239-245. (Pubitemid 30331108)
25. Ferrante, R.J.; Hantraye, P.; Brouillet, E.; Beal, M.F. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons isblocked by inhibition of neuronal nitric oxide synthase. Brain Res. 1999, 823, 177-182. (Pubitemid 29225506)
26. Pennathur, S.; Jackson-Lewis, V.; Przedborski, S.; Heinecke, J.W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'- dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridinetreated mice, a model of oxidative stress in parkinson's disease. J. Biol. Chem. 1999, 274, 34621-34628. (Pubitemid 129509499)
27. Klivenyi, P.; Andreassen, O.A.; Ferrante, R.J.; Dedeoglu, A.; Mueller, G.; Lancelot, E.; Bogdanov, M.; Andersen, J.K.; Jiang, D.; Beal, M.F. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J. Neurosci. 2000, 20, 1-7. (Pubitemid 30220485)
28. Wu, D.C.; Jackson-Lewis, V.; Vila, M.; Tieu, K.; Teismann, P.; Vadseth, C.; Choi, D.K.; Ischiropoulos, H.; Przedborski, S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrhydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2002, 22, 1763-1771. (Pubitemid 35386294)
29. He, Y.; Imam, S.Z.; Dong, Z.; Jankovic, J.; Ali, S.F.; Appel, S.H.; Le, W. Role of nitric oxide in rotenone-induced nigro-striatal injury. J. Neurochem. 2003, 86, 1338-1345. (Pubitemid 37174251)
30. Iravani, M.M.; Haddon, C.O.; Rose, S.; Jenner, P. 3-Nitrotyrosine- dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res. 2006, 1067, 256-262. (Pubitemid 43133096)
31. Zhang, L.; Dawson, V.L.; Dawson, T.M. Role of nitric oxide in Parkinson's disease. Pharmacol. Ther. 2006, 109, 33-41. (Pubitemid 41740813)
32. Good, P.F.; Hsu, A.; Werner, P.; Pearl, D.P.; Olanow, C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 1998, 57, 338-342. (Pubitemid 28182632)
33. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurting, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290, 985-989.
34. Mayer, B.; Hemmens, B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci. 1997, 22, 477-481. (Pubitemid 27515914)
35. Lewis, R.S.; Deen, W.M. Kinetics of the reaction of nitric oxide with oxygen in aqueous solutions. Chem. Res. Toxicol. 1994, 7, 568-574. (Pubitemid 24232355)
36. Ferrer-Sueta, G.; Radi, R. Chemical biology of peroxynitrite: kinetics, diffusion, and radicals. ACS Chem. Biol. 2009, 4, 161-177.
37. van der Vliet, A.; Eiserich, J.P.; Halliwell, B.; Cross, C.E. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J. Biol. Chem. 1997, 272, 7617-7625. (Pubitemid 27137309)
38. Zecca, L.; Fariello, R.G.; Galimberti, M.; Racagni, G.; Ambrosini, A. Changes in nitric oxide metabolite levels in stimulated substantia nigra neurons. NeuroReport 1997, 8, 2121-2125. (Pubitemid 27319657)
39. Milstien, S.; Sakai, N.; Brew, B.J.; Krieger, C.; Vickers, J.H.; Saito, K.; Heyes, M.P. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J. Neurochem. 1994, 63, 1178-1180. (Pubitemid 24266637)
40. Qureshi, G.A.; Baig, S.; Bednar, I.; Sodersten, P.; Forsberg, G.; Siden, A. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. NeuroReport 1995, 6, 1642-1644.
41. Shergill, J.K.; Cammack, R.; Cooper, C.E.; Cooper, J.M.; Mann, V.M.; Shapira, A.H.V. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. Biochem. Biophys. Res. Commun. 1996, 228, 298-305. (Pubitemid 26396069)
42. Byun, J.; Henderson, J.P., Mueller, D.M.; Heinecke, J.W. 8-Nitro-2'- deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by myeloperoidase-hydrogen peroxide-nitrite system of activated human phagocytes. Biochemistry 1999, 38, 2590-2600.
43. Beckman, J.S.; Koppenol, W.H.; Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996, 271, C1424-C1437.
44. Gow, A.; Duran, D.; Thom, S.R.; Ischiropoulos, H. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration. Arch. Biochem. Biophys. 1996, 333, 42-48. (Pubitemid 26276972)
45. Blanchard-Fillion, B.; Prou, D.; Polydoro, M.; Spielberg, D.; Tsika, E.; Wang, Z.; Hazen, S.L.; Koval, M.; Przedborski, S.; Ischiropoulos, H. Metabolism of 3-nitrotyrosine induces apoptotic death in dopaminergic cells. J. Neurosci. 2006, 26, 6124-6130.
46. Peluffo, H.; Shacka, J.J.; Ricart, K.; Bisig, C.G.; Martinez-Palma, L.; Pritsch, O.; Kamaid, A.; Eiserich, J.P.; Crow, J.P.; Barbeito, L.; Estevez, A.G. Induction of motor neuron apoptosis by free 3-nitro-L-tyrosine. J. Neurochem. 2004, 89, 602-612. (Pubitemid 38534146)
47. Zedda, M.; Lepore, G.; Gadau, S.; Manca, P.; Farina, V. Morphological and functional changes induced by the amino acid analogue 3-nitrotyrosine in mouse neuroblastoma and rat glioma cell lines. Neurosci. Lett. 2004, 363, 190-193. (Pubitemid 38692617)
48. Murray, J.; Taylor, S.W.; Zhang, B.; Ghosh, S.S.; Capaldi, R.A. Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J. Biol. Chem. 2003, 278, 37223-37230. (Pubitemid 37175238)
49. Bharath, S.; Andersen, J.K. Glutathione depletion in a midbrain-derived immortalized dopaminergic cell line results in limited tyrosine nitration of mitochondrial complex I subunits: implications for Parkinson's disease. Antioxid. Redox Signal. 2005, 7, 900-910. (Pubitemid 40967141)
50. Sulzer, D.; Bogulavsky, J.; Larsen, K.E.; Behr, G.; Karatekin, E.; Kleinman, M.H.; Turro, N.; Krantz, D.; Edwards, R.H.; Greene, L.A.; Zecca, L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vescicles. Proc. Natl. Acad. Sci. USA 2000, 97, 11869-11874.
51. Sulzer, D.; Zecca, L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 2000, 1, 181-195.
52. Hearing, V. J. The expanding role and presence of neuromelanins in the human brain - why gray matter is gray. Pigment Cell Melanoma Res. 2009, 22, 10-11.
53. Zecca, L.; Zucca, F.A.; Costi, P.; Tampellini, D.; Gatti, A.; Gerlach, M.; Riederer, P.; Fariello, R.G.; Ito, S.; Gallorini, M.; Sulzer, D. The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. J. Neural Transm. Suppl. 2003, 65, 145-55. (Pubitemid 38339952)
54. Zucca, F.A.; Giaveri, G.; Gallorini, M.; Alberini, A.; Toscani, M.; Pezzoli, G.; Lucius, R.; Wilms, H.; Sulzer, D.; Ito, S.; Wakamatsu, K.; Zecca, L. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res. 2004, 17, 610-617. (Pubitemid 39551306)
55. Zecca, L.; Zucca, F.A.; Wilms, H.; Sulzer, D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 2003, 26, 578-580. (Pubitemid 37338363)
56. Zecca, L.; Bellei, C.; Costi, P.; Albertini, A.; Monzani, E.; Casella, L.; Gallorini, M.; Bergamaschi, L.; Moscatelli, A.; Turro, N.J.; Eisner, M.; Crippa, P.R.; Ito, S.; Wakamatsu, K.; Bush, W.D.; Ward, W.C.; Simon, J.D.; Zucca, F.A. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci. USA 2008, 105, 17567-17572.
57. Zecca, L.; Casella, L.; Albertini, A.; Bellei, C.; Zucca, F.A.; Engelen, M.; Zadlo, A.; Szewczyk, G.; Zareba, M.; Sarna, T. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 2008, 106, 1866-1875.
58. Ito, S.; Wakamatsu, K. In The pigmentary system: physiology and pathophysiology; Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.P., Eds.; Blackwell Publishing: New York, 2006; pp. 282- 310.
59. Greggio, E.; Bergantino, E.; Carter, D.; Ahmad, R.; Costin, G.E.; Hearing, V.J.; Clarimon, J., Singleton, A.; Eerola, J.; Hellstrom, O.; Tienari, P.J.; Miller, D.W.; Beilina, A.; Bubacco, L.; Cookson, M.R. Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J. Neurochem. 2005, 93, 246-256. (Pubitemid 40463533)
60. Pezzella, A.; Crescenzi, O.; Natangelo, A.; Panzella, L.; Napolitano, A.; Navaratnam, S.; Edge, R.; Land, E.J.; Barone, V.; d'Ischia, M. Chemical, pulse radiolysis and density functional studies of a new, labile 5,6- indolequinone and its semiquinone. J. Org. Chem. 2007, 72, 1595-1603. (Pubitemid 46355455)
61. Pezzella, A.; Panzella, L.; Crescenzi, O.; Napolitano, A.; Navaratman, S.; Edge, R.; Land, E.J.; Barone, V.; d'Ischia, M. Short-lived quinonoid species from 5,6-dihydroxyindole dimers en route to eumelanin polymers: integrated chemical, pulse radiolytic, and quantum mechanical investigation. J. Am. Chem. Soc. 2006, 128, 15490-15498. (Pubitemid 44876025)
62. Bisaglia, M.; Mammi, S.; Bubacco, L. Kinetic and structural analysis of the early oxidation products of dopamine. Analysis of the interaction with α- synuclein. J. Biol. Chem. 2007, 282, 15597-15605.
63. Chen, L.; Ding, Y.; Cagniard, B.; Van Laar, A.D.; Mortimer, A.; Chi, W.; Hastings, T.G.; Kang, U.J.; Zhuang, X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 2008, 28, 425-433.
64. Paris, I.; Lozano, J.; Perez-Pastene, C.; Muñoz, P.; Segura-Aguilar, J. Molecular and neurochemical mechanisms in PD pathogenesis. Neurotox Res. 2009, 16, 271-279.
65. Napolitano, A.; Pezzella, A.; Prota, G. New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to NE and the neurotoxins 6-hydroxydopamine and 6,7- dihydroxytetrahydroisoquinoline. Chem. Res. Toxicol. 1999, 12, 1090-1097.
66. Napolitano, A.; Pezzella, A.; Prota, G. 6,7-Dihydroxy-1,2,3,4- tetrahydroisoquinoline formation by iron mediated dopamine oxidation: a novel route to endogenous neurotoxins under oxidative stress conditions. Tetrahedron Lett. 1999, 40, 2833-2836. (Pubitemid 29145074)
67. Pezzella, A.; d'Ischia, M.; Napolitano, A.; Misuraca, G.; Prota, G. Ironmediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 1997, 40, 2211-2216. (Pubitemid 27284359)
68. Napolitano, A.; Crescenzi, O.; Pezzella, A.; Prota, G. Generation of the neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of dopamine. J. Med. Chem. 1995, 38, 917-922.
69. Tranzer, J.P.; Thoenen, H. An electron microscopic study of selective acute degeneration of sympathetic nerve terminals after administration of 6- hydroxydopamine. Experientia 1968, 24, 155-156.
70. Hanrott, K.; Gudmunsen, L.; O'Neill, M.J.; Wonnacott, S. 6- Hydroxydopamine-induced apoptosis is mediated via extracellular autooxidation and caspase 3-dependent activation of protein kinase Cα. J. Biol. Chem. 2006, 281, 5373-5382. (Pubitemid 43847631)
71. Ding, Y.M.; Jaumotte, J.D.; Signore, A.P.; Zigmond, A.P. Effects of 6- hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J. Neurochem. 2004, 89, 776-787. (Pubitemid 38534162)
72. Tsao, C.W.; Cheng, J.T.; Lin, Y.S. Down-regulation of Bcl-2, activation of caspases, and involvement of reactive oxygen species in 6- hydroxydopamine-induced thymocyte apoptosis. Neuroimmunomodulation 2002, 10, 328-336.
73. Blum, D.; Torch, S.; Lambeng, N.; Nissou, M.; Benabid, A.L.; Sadoul, R.; Verna, J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65, 135-172. (Pubitemid 32524182)
74. Blum, D.; Torch, S.; Nissou, M.; Benabid, A.L.; Verna, J.M. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci. Lett. 2000, 283, 193-196. (Pubitemid 30168965)
75. Soto-Otero, R.; Mendez-Alvarez, E.; Hermida-Ameijeiras, A.; Munoz- Patino, A.M.; Labandeira-Garcia, J.L. Autoxidation and neurotoxicity of 6- hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 2000, 74, 1605-1612. (Pubitemid 30163982)
76. Manini, P.; Panzella, L.; Napolitano, A.; d'Ischia, M. A novel hydrogen peroxide-dependent oxidation pathway of dopamine via 6-hydroxydopamine. Tetrahedron 2003, 59, 2215-2221. (Pubitemid 36331896)
77. Palumbo, A.; Napolitano, A.; Barone, P.; d'Ischia, M. Nitrite- and peroxidedependent oxidation pathways of dopamine: 6-nitrodopamine and 6- hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration. Chem. Res. Toxicol. 1999, 12, 1213-1222. (Pubitemid 30013532)
78. d'Ischia, M.; Costantini, C. Nitric oxide-induced nitration of catecholamine neurotransmitters: a key to neuronal degeneration? Bioorg. Med. Chem. 1995, 3, 923-927.
79. Daveu, C.; Servy, C.; Dendane, M.; Marin, P.; Ducrocq, C. Oxidation and nitration of catecholamines by nitrogen oxides derived from nitric oxide. Nitric Oxide 1997, 1, 134-143.
80. de la Breteche, M.L.; Servy, C.; Lenfant, M.; Ducrocq, C. Nitration of catecholamines with nitrogen oxides in mild conditions. Tetrahedron Lett. 1994, 35, 7231-7232.
81. Shintani, F.; Kinoshita, T.; Kanba, S.; Ishikawa, T., Suzuki, E., Sasakawa, N.; Kato, R.; Asai, M.; Nakai, T. Bioactive 6-nitronorepinephrine identified in mammalian brain. J. Biol. Chem. 1996, 271, 13561-13565. (Pubitemid 26185402)
82. Macarthur, H.; Mattamal, M.B.; Westfall, T.C. A new perspective on the inhibitory role of nitric oxide in sympathetic neurotransission. Biochem. Biophys. Res. Commun. 1995, 216, 686-692.
83. Chiari, A.; Li, X.H.; Xu, Z.; Pan, H.L.; Eisenach, J.C. Formation of 6- nitronorepinephrine from nitric oxide and norepinephrine in the spinal cord and its role in spinal analgesia. Neuroscience 2000, 101, 189-196.
84. Palumbo, A.; Astarita, G.; d'Ischia, M.; Inhibition of neuronal nitric oxide synthase by 6-nitrocatecholamines, putative reaction products of nitric oxide with catecholamines under oxidative stress conditions. Biochem. J. 2001, 356, 105-110. (Pubitemid 34275711)
85. Palumbo, A.; Napolitano, A.; d'Ischia, M. Nitrocatechols versus nitrocatecholamines as novel competitive inhibitors of neuronal nitric oxide synthase: lack of the aminoethyl side chain determines loss of tetrahydrobiopterin-antagonizing properies. Bioorg. Med. Chem. Lett. 2002, 12, 13-16. (Pubitemid 34008559)
86. Palumbo, A.; Napolitano, A.; Carraturo, A.; Russo, G.L.; d'Ischia, M. Oxidative conversion of 6-nitrocatecholamines to nitrosating products: a possible contributory factor in nitric oxide and catecholamine neurotoxicity associated with oxidative stress and acidosis. Chem. Res. Toxicol. 2001, 14, 1296-1305. (Pubitemid 32911470)
87. Baez, S.; Linderson, Y.; Segura-Aguilar, J. Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem. Mol. Med. 1995, 54, 12-18.
88. Arriagada, C.; Paris, I.; Sanchez de las Matas, M.J.; Martinez-Alvarado, P.; Crdenas, S.; Castaneda, P.; Graumann, R.; Perez-Pastene, C.; Olea-Azar, C.; Couve, E.; Herrero, M.T.; Caviedes, P.; Segura-Aguilar, J. On the neurotoxicity mechanism of leukoaminochrome-o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol. Disease 2004, 16, 468-477. (Pubitemid 38757327)
89. Graumann, R.; Paris, I.; Martinez-Alvarado, P.; Rumanque, P.; Perez- Pastene, C.; Cardenas, S.P.; Marin, P.; Diaz-Grez, F.; Caviedes, R.; Segura- Aguilar, J. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase. Pol. J. Pharmacol. 2002, 54, 573-579. (Pubitemid 36124506)
90. Paris, I.; Cardenas, S.; Lozano, J.; Perez-Pastene, C.; Graumann, R.; Riveros, A.; Caviedes, P.; Segura-Aguilar, J. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease. Neurotox. Res. 2007, 12, 125-134.
91. Segura-Aguilar, J.; Metodiewa, D.; Welch, C.J. Metabolic activation of dopamine-o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1998, 1381, 1-6. (Pubitemid 28248110)
92. Rosengren, E.; Linder-Eliasson, E.; Carlsson, A. Detection of 5-Scysteinyldopamine in human brain. J. Neural Transm. 1985, 63, 247-253.
93. Baez, S.; Segura-Aguilar, J.; Widersten, M.; Johansson, A-S.; Mannervik, B. Glutathione transferases catalyze the detoxication of oxidized metabolites (oquinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 1997, 342, 25-28. (Pubitemid 27229361)
94. Dagnino-Subiabre, A.; Cassels, B.K.; Johansson, A-S.; Baez, S.; Mannervik, B.; Segura-Aguilar, J. Glutathione transferase M2-2 prevents formation of neurotoxic aminochrome and dopachrome by catalyzing the conjugation of dopamine and dopa ortho-quinone. Biochem. Biophys. Res. Commun. 2000, 274, 32-36. (Pubitemid 30496752)
95. Segura-Aguilar, J.; Baez, S.; Widersten, M.; Welch, C.J.; Mannervik, B. Human class glutathione transferases, in particular isoenzymes M2-2, catalyze detoxication of dopamine metabolite aminochrome. J. Biol. Chem. 1997, 272, 5727-5731. (Pubitemid 27102401)
96. Schultzberg, M.; Segura-Aguilar, J.; Lind, L. Distribution of DT-diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 1998, 27, 763-766.
97. Manini, P.; Panzella, L.; Napolitano, A.; d'Ischia, M. Oxidation chemistry of norepinephrine: partitioning of the o-quinone between competing cyclization and chain breakdown pathways and their roles in melanin formation. Chem. Res. Toxicol. 2007, 20, 1549-1555. (Pubitemid 350057226)
98. Manini, P.; Pezzella, A.; Panzella, L.; Napolitano, A.; d'Ischia, M. New insight into the oxidative chemistry of noradrenaline: competitive o-quinone cyclisation and chain fission routes leading to an unusual 4-[bis-(1H-5,6- dihydroxyindol-2-yl)methyl]-1,2-dihydroxybenzene derivative. Tetrahedron 2005, 61, 4075-4080. (Pubitemid 40718714)
99. Tsunoda, M.; Uchino, E.; Imai, K.; Funatsu, T. Oxidative stress increased 6- nitronorepinephrine and 6-nitroepinephrine concentrations in rat brain. Biomed. Chromatogr. 2008, 22, 572-574.
100. Sofic, E.; Lange, K.W.; Jellinger, K.; Riederer, P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 1992, 142, 128-130.
101. Sian, J.; Dexter, D.; Lees, A.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann. Neurol. 1994, 36, 356-361.
102. Dexter, D.T.; Sian, J.; Rose, S.; Hindmarsh, J.G.; Mann, V.M.; Cooper, J.M.; Wells, F.R.; Daniel, S.E.; Lees, A.J.; Schapira, A.H.V.; Jenner, P.; Marsden, C.D. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 1994, 35, 38-44. (Pubitemid 24027604)
103. Zhang, F.; Dryhurst, G. Effects of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 1994, 37, 1084-1098. (Pubitemid 24145369)
104. Shen, X-M.; Dryhurst, G. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 1996, 9, 751-763. (Pubitemid 26181626)
105. Dryhurst, G. In Glutathione in the nervous system. Shaw, C.A., Ed.; Taylor and Francis: Washington DC, 1997; pp. 305-342.
106. Zhang, F.; Dryhurst, G. Oxidation chemistry of dopamine: possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg. Chem. 1993, 21, 392-410. (Pubitemid 24026003)
107. Shen, X-M.; Dryhurst, G. Oxidation chemistry of (-)-norepinephrine in the presence of L-cysteine. J. Med. Chem. 1996, 39, 2018-2029. (Pubitemid 26163252)
108. Xin, W.; Shen, X-M.; Li, H.; Dryhurst, G. Oxidative metabolites of 5-Scysteinylnorepinephrine are irreversible inhibitors of mitochondrial complex I and the α-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes: possible implications for neurodegenerative brain disorders. Chem. Res. Toxicol. 2000, 13, 749-760. (Pubitemid 30663453)
109. Shen, X-M.; Dryhurst, G. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem. Res. Toxicol. 1998, 11, 824-837. (Pubitemid 28350733)
110. Palumbo, A.; d'Ischia, M.; Misuraca, G.; De Martino, L.; Prota, G. Iron- and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine. Biochim. Biophys. Acta 1995, 1245, 255-261.
111. Shen, X-M.; Zhang, F.; Dryhurst, G. Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem. Res. Toxicol. 1997, 10, 147-155. (Pubitemid 27091882)
112. Napolitano, A.; Di Donato, P.; Prota, G. New regulatory mechanisms in the biosynthesis of pheomelanins: rearrangement vs redox exchange reaction routes of a transient 2H-1,4-benzothiazine-o-quinonimine intermediate. Biochim. Biophys. Acta 2000, 1475, 47-54. (Pubitemid 30259238)
113. Li, H.; Shen, X-M.; Dryhurst, G. Brain mitochondria catalyzed the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3- carboxylic acid (DHBT-1) to intermeiates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 1998, 71, 2049-2062. (Pubitemid 28491561)
114. Li, H.; Dryhurst, G. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex. J. Neural Transm. 2001, 108, 1363-1374. (Pubitemid 34020442)
115. Shen, X-M.; Li, H.; Dryhurst, G. Oxidative metabolites of 5-Scysteinyldopamine inhibit the α-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease. J. Neural Transm. 2000, 107, 959-978.
116. Satori, A.; Marchitti, R.; Deitrich, A.; Vasiliou, V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase Pharmacol. Rev. 2007, 59, 125-150. (Pubitemid 46855437)
117. Nagatsu, T. Amine-related neurotoxins in Parkinson's disease. Past, present, and future. Neurotoxicol. Teratol. 2002, 24, 565-569. (Pubitemid 35013517)
118. Mravec, B. Salsolinol, a derivate of dopamine, is a possible modulator of catecholaminergic transmission: a review of recent developments. Physiol. Res. 2006, 55, 353-364. (Pubitemid 44291092)
119. Maruyama, W.; Abe, T.; Tohgi, H.; Dostert, P.; Naoi, M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsoninan cerebrospinal fluid. Ann. Neurol. 1996, 40, 119-122. (Pubitemid 26250152)
120. Maruyama, W.; Narabayashi, H.; Dostert, P.; Naoi, M. Stereospecific occurrence of a parkinsonian-inducing catechol isoquinoline, N-methyl-(R)- salsolinol, in the human intraventricular fluid. J. Neural Transm. 1996, 103, 1069-1076. (Pubitemid 26383836)
121. Maruyama, W.; Sobue, G.; Matsubara, K.; Hashizume, Y.; Dostert, P.; Naoi, M. A dopaminergic neurotoxin, 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4- tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigrostriatal system of the human brain. Neurosci. Lett. 1997, 223, 61-64. (Pubitemid 27093020)
122. Musshoff, F.; Schmidt, P.; Dettmeyer, R.; Priemer, F.; Wittig, H.; Madea, B. A systematic regional study of dopamine and dopamine-derived salsolinol and norsalsolinol levels in human brain areas. Forensic Sci. Int. 1999, 105, 1-11. (Pubitemid 29467479)
123. Naoi, M.; Maruyama, W.; Akao, Y.; Yi, H. Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease. Neurotoxicol. Teratol. 2002, 24, 579-591. (Pubitemid 35013519)
124. Toth, B.E.; Homicsko, K.; Radnai, B.; Maruyama, W.; Demaria, J.E.; Vecsernyes, M.; Fekete, M.I.K.; Fulop, F.; Naoi, M.; Freeman, M.E.; Nagy, G.M. Salsolinol is a putative endogenous neuro-intermediate lobe prolactinreleasing factor. J. Neuroendocrinol. 2001, 13, 1042-1050. (Pubitemid 33100221)
125. Naoi, M.; Maruyama, W.; Nagy, G.M. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. NeuroToxicology 2004, 25, 193-204. (Pubitemid 38044181)
126. Naoi, M.; Maruyama, W.; Zhang, Y.H.; Takahashi, T.; Deng, Y.; Dostert, P. Enzymatic oxidation of the dopaminergic neurotoxin, 1(R),2(N)-dimethyl- 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1,2-dimethyl-6,7- dihydroxyisoquinolinium ion. Life Sci. 1995, 57, 1061-1066.
127. Takahashi, T.; Deng, Y.; Maruyama, W.; Dostert, P.; Kawai, M.; Naoi, M. Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4- tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J. Neural Transm. 1994, 98, 107-118.
128. Naoi, M.; Maruyama, W.; Dostert, P. Binding of 1,2(N)-dimethyl-6,7- dihydroxyisoquinolinium ion to melanin: effects of ferrous and ferric ion on the binding. Neurosci. Lett. 1994, 171, 9-12. (Pubitemid 24142076)
129. Naoi, M.; Maruyama, W.; Dostert, P.; Kohda, K.; Kaiya, T. A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol. Neurosci. Lett. 1996, 212, 183-186. (Pubitemid 26245680)
130. Naoi, M.; Maruyama, W.; Matsubara, K.; Hashizume, Y. A neutral Nmethyltransferase activity in the striatum determines the level of an endogenous MPP+-like neurotoxin, 1,2-dimethyl-6,7- dihydroxyisoquinolinium ion, in the substatntia nigra of human brains. Neurosci. Lett. 1997, 235, 81-84. (Pubitemid 27471110)
131. Yi, H.; Akao, Y.; Maruyama, W.; Chen, K.; Shih, J.; Naoi, M. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem. 2006, 96, 541-549.
132. Naoi, M.; Maruyama, W.; Dostert, P.; Hashizume, Y.; Nakahara, D.; Takahashi, T.; Ota, M. Dopamine-derived endogenous 1(R),2(N)-dimethyl- 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res. 1996, 709, 285-295.
133. Naoi, M.; Maruyama, W.; Akao, Y.; Zhang, J.; Parvez, H. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. Toxicology 2000, 153, 123-141.
134. Maruyama, W.; Naoi, M.; Kasamatsu, T.; Hashizume, Y.; Takahashi, T.; Kohda, K.; Dostert, P. An endogenous dopaminergic neurotoxin, N-methyl- (R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 1997, 69, 322-329. (Pubitemid 27274188)
135. Maruyama, W.; Boulton, A.A.; Davis, B.A.; Dostert, P.; Naoi, M. Enantiospecific induction of apoptosis by an endogenous neurotoxin, Nmethyl( R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J. Neural Transm. 2001, 108, 11-24. (Pubitemid 32692610)
136. Manini, P.; d'Ischia, M.; Prota, G. An unusual decarboxylative Maillard reaction between L-DOPA and D-glucose under biomimetic conditions: factors governing competition with Pictet-Spengler condensation. J. Org. Chem. 2001, 66, 5048-5053. (Pubitemid 32867513)
137. Manini, P.; d'Ischia, M.; Lanzetta, R.; Parrilli, M.; Prota, G. Reaction of dopamine with D-glyceraldehyde under biomimetic conditions: stereoselective formation of tetrahydroisoquinolines and rate-accelerating effects of transition metal ions. Bioorg. Med. Chem. 1999, 7, 2525-2530. (Pubitemid 30122754)
138. Manini, P.; d'Ischia, M.; Prota, G. Pictet-Spengler condensation of the antiparkinsonian drug L-DOPA with D-glyceraldehyde. Opposite kinetic effects of Fe3+ and Cu2+ ions and possible implications for the origin of therapeutic side effects. Bioorg. Med. Chem. 2001, 9, 923-929.
139. Pezzella, A.; Prota, G.; Formation of novel tetrahydroisoquinoline retinoids by Pictet-Spengler reaction of dopamine and retinaldehyde under conditions of relevance to biological environments. Tetrahedron Lett. 2002, 43, 6719-6721. (Pubitemid 35245880)
140. Manini, P.; Panzella, L.; Tedesco, I.; Petitto, F.; Russo, G.L.; Napolitano, A.; Palumbo, A.; d'Ischia, M. Tetrahydrobiisoquinoline derivatives by reaction of dopamine with glyoxal: a novel potential degenerative pathway of catecholamines under oxidative stress conditions. Chem. Res. Toxicol. 2004, 17, 1190-1198. (Pubitemid 39265874)
141. Kuhn, D.M.; Arthur, R.E., Jr; Thomas, D.M.; Elferink, L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redoxcycling quino-protein: possible relevance to Parkinson's disease. J. Neurochem. 1999, 73, 1309-1317. (Pubitemid 29395493)
142. Kuhn, D.M.; Arthur, R., Jr. Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J. Neurosci. 1998, 18, 7111-7117. (Pubitemid 28425798)
143. Bolton, J.L.; Trush, M.A.; Penning, T.M.; Dryhurst, G.; Monks, T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 2000, 13, 135-160. (Pubitemid 30169958)
144. Mosharov, E.V.; Staal, R.G.W.; Bové, J.; Prou, D.; Annaniya, A.; Markov, D.; Poulsen, N.; Larsen, K.E.; Moore, C.M.H.; Troyer, M.D.; Edwards, R.H.; Przedborski, S.; Sulzer, D. α-Synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 2006, 26, 9304-9311. (Pubitemid 44359856)
145. Lévay, G.; Bodell, W.J. Detection of dopamine-DNA adducts: potential role in Parkinson's disease. Carcinogenesis 1993, 14, 1241-1245. (Pubitemid 23193560)
146. Berman, S.B.; Hastings, T.G. Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J. Neurochem. 1997, 69, 1185-1196.
147. Whitehead, R.E.; Ferrer, J.V.; Javitch, J.A.; Justice, J.B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 2001, 76, 1242-1251. (Pubitemid 32167397)
148. Akagawa, M.; Ishii, Y.; Ishii, T.; Shibata, T.; Yotsu-Yamashita, M.; Suyama, K.; Uchida, K. Metal-catalyzed oxidation of protein-bound dopamine. Biochemistry 2006, 45, 15120-15128. (Pubitemid 44937025)
149. Van Laar, V.S.; Dukes, A.A.; Cascio, M.; Hastings, T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 2008, 29, 477-489.
150. Schlattner, U.; Forstner, M.; Eder, M.; Stachowiak, O.; Fritz-Wolf, K.; Wallimann, T. Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach. Mol. Cell Biochem. 1998, 184, 125-140. (Pubitemid 28398605)
151. Lenz, H.; Schmidt, M.; Welge, V.; Kueper, T.; Schlattner, U.; Wallimann, T.; Elsasser, H.P.; Wittern, K.P.; Wenck, H.; Staeb, F.; Blatt, T. Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology. Mol. Cell Biochem. 2007, 306, 153-162. (Pubitemid 350001827)
152. Speer, O.; Back, N.; Buerklen, T.; Brdiczka, D.; Koretsky, A.; Wallimann, T.; Eriksson, O. Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and the outer membrane. Biochem. J. 2005, 385, 445-450. (Pubitemid 40165077)
153. John, G.B.; Shang, Y.; Li, L.; Renken, C.; Mannella, C.A.; Selker, J.M.; Rangell, L.; Bennett, M.J.; Zha, J. The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol. Biol. Cell 2005, 16, 1543-1554. (Pubitemid 40349586)
154. Nicolis, S.; Zucchelli, M.; Monzani, E.; Casella, L. Myoglobin modification by enzyme-generated dopamine reactive species. Chem. Eur. J. 2008, 14, 8661-8673.
155. Monzani, E.; Nicolis, S.; Roncone, R.; Barbieri, M.; Granata, A.; Casella, L. Protein self-modification by heme-generated reactive species. IUMB Life 2008, 60, 41-56.
156. Perez, R.G.; Waymire, J.C.; Lin, E.; Liu, J.J.; Guo, F.; Zigmond, M.J. A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22, 3090-3099. (Pubitemid 35379198)
157. Lee, F.J.; Liu, F.; Pristupa, Z.B.; Niznik, H.B. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamineinduced apoptosis. FASEB J. 2001, 15, 916-926. (Pubitemid 32290778)
158. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392, 605-608. (Pubitemid 28207717)
159. Couzin, J. Dopamine may sustain toxic protein. Science 2001, 294, 1257-1258. (Pubitemid 33063057)
160. Hasegawa, T.; Matsuzaki-Kobayashi, M.; Takeda, A; Sugeno, N.; Kikuchi, A.; Furukawa, K.; Perry, G.; Smith, M.A.; Itoyama, Y. α-Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Lett. 2006, 580, 2147-2152.
161. Takeda, A.; Hasegawa, T.; Matsuzaki-Kobayashi, M.; Sugeno, N.; Kikuchi, A.; Itoyama, Y.; Furukawa, K. Mechanisms of neuronal death in synucleinopathy. J. Biomed. Biotechnol. 2006, 2006, 19365.
162. Hastings, T.G.; Lewis, D.A.; Zigmond, M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 1956-1961. (Pubitemid 26079862)
163. Kuhn, D.M.; Arthur, R.E. Jr.; Thomas, D.M.; Elferink, L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redoxcycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 1999, 73, 1309-1317. (Pubitemid 29395493)
164. LaVoie, M.J.; Hastings, T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role of extracellular dopamine. J. Neurosci. 1999, 19, 1484-1491. (Pubitemid 29088929)
165. Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 2002, 418, 291. (Pubitemid 34790672)
166. LaVoie, M.J.; Ostaszewski, B.L.; Weihofen, A.; Schlossmacher, M.G.; Selkoe, D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 2005, 11, 1214-1221. (Pubitemid 43093669)